Cancer Research
Table of Contents
American Association for Cancer Research

August 15, 2014 • Volume 74 • Number 16

BREAKING ADVANCES

REVIEWS

PRIORITY REPORT

CLINICAL STUDIES

INTEGRATED SYSTEMS AND TECHNOLOGIES

MICROENVIRONMENT AND IMMUNOLOGY

MOLECULAR AND CELLULAR PATHOBIOLOGY

Table of Contents

Table of Contents

Table of Contents

TUMOR AND STEM CELL BIOLOGY

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

Expression of the multidrug resistance protein ABCG2 confers chemoresistance to CSC where it serves as a potential biomarker and therapeutic target. Afatinib, a small molecule inhibitor of the tyrosine kinases EGFR, HER2, and HER4, can enhance the antitumor effect of the DNA damaging drug topotecan *in vitro* and *in vivo*. Immunofluorescence microscopic analysis showed that afatinib significantly decreased the cell surface expression of ABCG2 in a concentration-dependent manner. For details, see article by X.-K. Wang and colleagues on page 4431.



AACR American Association for Cancer Research

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

74 (16)

Cancer Res 2014;74:4209-4562.